AU2017207359C1 - Method of treating C3 glomerulopathy - Google Patents

Method of treating C3 glomerulopathy Download PDF

Info

Publication number
AU2017207359C1
AU2017207359C1 AU2017207359A AU2017207359A AU2017207359C1 AU 2017207359 C1 AU2017207359 C1 AU 2017207359C1 AU 2017207359 A AU2017207359 A AU 2017207359A AU 2017207359 A AU2017207359 A AU 2017207359A AU 2017207359 C1 AU2017207359 C1 AU 2017207359C1
Authority
AU
Australia
Prior art keywords
compound
human
glomerulopathy
group
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017207359A
Other languages
English (en)
Other versions
AU2017207359B2 (en
AU2017207359A1 (en
Inventor
Petrus BEKKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2017207359A1 publication Critical patent/AU2017207359A1/en
Application granted granted Critical
Publication of AU2017207359B2 publication Critical patent/AU2017207359B2/en
Publication of AU2017207359C1 publication Critical patent/AU2017207359C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017207359A 2016-01-14 2017-01-12 Method of treating C3 glomerulopathy Active AU2017207359C1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US62/278,788 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US62/280,346 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US62/347,450 2016-06-08
US201662397527P 2016-09-21 2016-09-21
US62/397,527 2016-09-21
PCT/US2017/013132 WO2017123716A1 (en) 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy

Publications (3)

Publication Number Publication Date
AU2017207359A1 AU2017207359A1 (en) 2018-07-26
AU2017207359B2 AU2017207359B2 (en) 2022-04-14
AU2017207359C1 true AU2017207359C1 (en) 2022-09-01

Family

ID=59312069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017207359A Active AU2017207359C1 (en) 2016-01-14 2017-01-12 Method of treating C3 glomerulopathy

Country Status (18)

Country Link
US (3) US20170202821A1 (enExample)
EP (1) EP3402486B1 (enExample)
JP (3) JP7339733B2 (enExample)
KR (1) KR102767008B1 (enExample)
CN (1) CN108601790A (enExample)
AU (1) AU2017207359C1 (enExample)
BR (2) BR112018014222A2 (enExample)
CA (1) CA3010735C (enExample)
ES (1) ES3026359T3 (enExample)
IL (1) IL260539B (enExample)
MA (1) MA43872A (enExample)
MX (2) MX2018008624A (enExample)
NZ (1) NZ744083A (enExample)
RU (1) RU2742888C2 (enExample)
SG (1) SG11201805828YA (enExample)
TW (1) TWI791423B (enExample)
WO (1) WO2017123716A1 (enExample)
ZA (1) ZA201804513B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577548T3 (es) 2008-12-22 2016-07-15 Chemocentryx, Inc. Antagonistas de C5aR
US9126939B2 (en) 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
CN106999481B (zh) 2014-09-29 2021-04-16 凯莫森特里克斯股份有限公司 制备C5aR拮抗剂的方法和中间体
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
MA43872A (fr) 2016-01-14 2021-05-19 Chemocentryx Inc Procédé de traitement d'une glomérulopathie à c3
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2019021091A1 (en) * 2017-07-27 2019-01-31 Procter & Gamble International Operations Sa SPRAYABLE, STABLE PHASE REFRIGERATING COMPOSITIONS COMPRISING SUSPENDED PARTICLES
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA
WO2019227102A1 (en) * 2018-05-25 2019-11-28 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers
MX2021002640A (es) * 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
PL3886820T3 (pl) 2018-11-30 2023-08-14 Chemocentryx, Inc. Postacie użytkowe będące kapsułkami
US12239645B2 (en) 2018-12-17 2025-03-04 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
WO2020182384A1 (en) 2019-03-11 2020-09-17 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
JP7635138B2 (ja) 2019-03-22 2025-02-25 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物
AU2021321901A1 (en) * 2020-08-07 2023-03-09 Kira Pharmaceuticals (Suzhou) Ltd. Compounds as C5ar inhibitors
US20220257580A1 (en) * 2020-12-21 2022-08-18 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
CN115192563B (zh) * 2022-05-09 2023-10-13 北京大学第一医院 C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163640A1 (en) * 2010-06-24 2011-12-29 Chemocentryx, Inc. C5ar antagonists

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
BR9913654A (pt) 1998-08-28 2001-11-27 Scios Inc Inibidores de p-38alfa quinase
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
WO2001085720A1 (en) 2000-05-05 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
ES2353077T3 (es) 2000-08-10 2011-02-25 Mitsubishi Tanabe Pharma Corporation Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
CN102050758A (zh) 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
YU23503A (sh) 2000-09-29 2006-03-03 Neurogen Corporation Mali molekuli kao modulatori receptora c5a visokog afiniteta
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
CN100488958C (zh) 2001-09-21 2009-05-20 三菱制药株式会社 3-取代的-4-嘧啶酮衍生物
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
WO2003082826A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
US20040014782A1 (en) 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
JP2006527756A (ja) 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク Ｎｋ１拮抗薬
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
BRPI0512535A (pt) 2004-06-24 2008-03-25 Incyte Corp compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006087543A1 (en) 2005-02-18 2006-08-24 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
RU2458051C2 (ru) 2005-11-24 2012-08-10 ДОМПЕ ФА.Р.МА С.п.А. (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции
DK2359834T5 (en) * 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US8198266B2 (en) * 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
RU2010102899A (ru) 2007-06-29 2011-08-10 Торрент Фармасьютикалз Лтд. (In) Новые замещенные пиперидоны в качестве индукторов hsp
WO2010019210A2 (en) 2008-08-11 2010-02-18 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
RS64039B1 (sr) 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
ES2577548T3 (es) 2008-12-22 2016-07-15 Chemocentryx, Inc. Antagonistas de C5aR
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
US8147400B1 (en) * 2011-01-17 2012-04-03 Coloplast A/S Penile implant with dilatant liquid
EP2864322B1 (en) * 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
DK2994488T3 (da) 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
CN106999481B (zh) 2014-09-29 2021-04-16 凯莫森特里克斯股份有限公司 制备C5aR拮抗剂的方法和中间体
MA43872A (fr) 2016-01-14 2021-05-19 Chemocentryx Inc Procédé de traitement d'une glomérulopathie à c3
NZ747259A (en) 2016-04-04 2022-11-25 Chemocentryx Inc Soluble c5ar antagonists
US20220257580A1 (en) 2020-12-21 2022-08-18 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163640A1 (en) * 2010-06-24 2011-12-29 Chemocentryx, Inc. C5ar antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Le Quintrec, M et al (2015) 'Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy' American Journal of Kidney Diseases 65(3): 484-489 *

Also Published As

Publication number Publication date
BR112018014222A2 (pt) 2018-12-11
NZ744083A (en) 2022-07-01
RU2742888C2 (ru) 2021-02-11
JP7339733B2 (ja) 2023-09-06
CA3010735C (en) 2023-06-13
CA3010735A1 (en) 2017-07-20
MX2022006069A (es) 2023-01-12
WO2017123716A1 (en) 2017-07-20
KR20180102642A (ko) 2018-09-17
US20220354837A1 (en) 2022-11-10
ES3026359T3 (en) 2025-06-11
ZA201804513B (en) 2024-01-31
MX2018008624A (es) 2018-12-10
EP3402486C0 (en) 2025-03-19
EP3402486B1 (en) 2025-03-19
US11285138B2 (en) 2022-03-29
RU2018129378A3 (enExample) 2020-05-20
JP2024110998A (ja) 2024-08-16
TW201726134A (zh) 2017-08-01
US11779576B2 (en) 2023-10-10
AU2017207359B2 (en) 2022-04-14
SG11201805828YA (en) 2018-08-30
CN108601790A (zh) 2018-09-28
MA43872A (fr) 2021-05-19
BR122024002810A2 (pt) 2024-03-12
TWI791423B (zh) 2023-02-11
RU2018129378A (ru) 2020-02-14
US20190201388A1 (en) 2019-07-04
IL260539B (en) 2021-05-31
JP2019501935A (ja) 2019-01-24
JP2021183625A (ja) 2021-12-02
JP2023126235A (ja) 2023-09-07
KR102767008B1 (ko) 2025-02-11
AU2017207359A1 (en) 2018-07-26
EP3402486A1 (en) 2018-11-21
EP3402486A4 (en) 2019-08-28
US20170202821A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
AU2017207359B2 (en) Method of treating C3 glomerulopathy
EP3439658B1 (en) Soluble c5ar antagonists
US20230105869A1 (en) C5aR INHIBITOR REDUCTION OF URINARY sCD163
US20220257580A1 (en) Treatment of c3 glomerulopathy using a c5a inhibitor
JP7788814B2 (ja) Ｃ３腎症を処置する方法
HK1262045B (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK1262045A1 (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK40004502B (en) Soluble c5ar antagonists

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 MAY 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 20 MAY 2022

FGA Letters patent sealed or granted (standard patent)